RNA technology Archives

Osteopetrosis ADO2 radiopaedia case ID 8037

News and Trends 16 May 2023

SiSaf siRNA therapy gets FDA designations to treat autosomal dominant osteopetrosis

SiSaf Ltd, an RNA delivery and therapeutics company, has announced that SIS-101-ADO, its siRNA therapeutic for patients with autosomal dominant osteopetrosis Type 2 (ADO2), has been granted orphan drug designation by the U.S. FDA. Also, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted rare pediatric disease designation […]

May 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 May 2023

Exothera partners with Quantoom and launches DNA business unit

Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in […]

May 5, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’

Arrowhead Pharmaceuticals Inc. has announced interim results from an ongoing phase 1/2 clinical study of ARO-RAGE, an investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for advanced glycation end products (RAGE) as a potential treatment for inflammatory pulmonary diseases, such as asthma. These data represent the first clinical demonstration of the […]

April 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

LincRNA discovery could lead to targeted treatments

Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up sections of our genome called topologically associating domains, or TADs. LincRNAs derived from TADs appear to act as markers indicating the specific kind of tissue they are within. When something […]

April 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models

Researchers from Tel Aviv University in Israel have revealed details of a new approach to the treatment of ovarian cancer using RNA-based nanodrugs – demonstrating an 80% survival rate in lab models.In a study at Tel Aviv University, the protein CKAP5 (cytoskeleton-associated protein) was used for the first time as a therapeutic target for RNA-based […]

April 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Mar 2023

Metabolism of RNA linked to leukemia

Researchers at Lund University Faculty of Medicine in Sweden have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome patients, MDS. In a study published in the Molecular Cell journal, they explain what makes hematopoietic stem cells acquire malignant traits in cancer. RNA splicing is […]

March 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Partnership formed to develop miRNA to treat pancreatic cancer

RNA delivery and therapeutics company SiSaf Ltd is to collaborate with the University of Leipzig in Germany to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer. The collaboration will combine SiSaf’s work in RNA delivery using its Bio-Courier silicon-stabilized hybrid lipid nanoparticles (sshLNPs) and the […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

Orbit Discovery Limited has entered into a master service agreement with SanegeneBio Inc., a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes. The agreement covers activities ranging from hit ID to cell-based […]

January 6, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Japanese research offers hope for Fukuyama muscular dystrophy patients

Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe neuromuscular disorder. One form of FCMD is caused by a genetic abnormality in the fukutin (FKTN) gene. The genetic anomaly blocks the chemical glycosylation of a biologically important […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

STORM Therapeutics doses first patient with drug targeting solid tumors

STORM Therapeutics Ltd, announced today that the first patient in a phase 1 study had been dosed with a drug targeting solid tumors. The biotech company works on discovering and developing new small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The patient was dosed with STC-15, STORM’s clinical candidate. It […]

November 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

BIA and Exopharm sign joint research agreement to develop integrated technology

Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […]

November 23, 2022 - 4 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us